PeptiDream Balance Sheet Health
Financial Health criteria checks 5/6
PeptiDream has a total shareholder equity of ¥58.5B and total debt of ¥20.3B, which brings its debt-to-equity ratio to 34.7%. Its total assets and total liabilities are ¥93.4B and ¥35.0B respectively. PeptiDream's EBIT is ¥24.5B making its interest coverage ratio 72.7. It has cash and short-term investments of ¥50.4B.
Key information
34.7%
Debt to equity ratio
JP¥20.28b
Debt
Interest coverage ratio | 72.7x |
Cash | JP¥50.42b |
Equity | JP¥58.47b |
Total liabilities | JP¥34.96b |
Total assets | JP¥93.43b |
Recent financial health updates
Recent updates
PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
Nov 18Is PeptiDream (TSE:4587) Using Too Much Debt?
Nov 15PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
Oct 31Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?
Oct 15PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 29PeptiDream Inc. Just Beat Revenue Estimates By 13%
Aug 12PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Jun 30News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Jun 02PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
Apr 30Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Apr 29PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
Mar 03Financial Position Analysis
Short Term Liabilities: 4587's short term assets (¥58.9B) exceed its short term liabilities (¥16.8B).
Long Term Liabilities: 4587's short term assets (¥58.9B) exceed its long term liabilities (¥18.2B).
Debt to Equity History and Analysis
Debt Level: 4587 has more cash than its total debt.
Reducing Debt: 4587's debt to equity ratio has increased from 0% to 34.7% over the past 5 years.
Debt Coverage: 4587's debt is well covered by operating cash flow (133.5%).
Interest Coverage: 4587's interest payments on its debt are well covered by EBIT (72.7x coverage).